To investigate whether donepezil is associated with a greater risk of hospitalization for malignant arrhythmias compared to other AChEIs.
Approach:
Study Design: A population-based retrospective cohort study of individuals aged 66 and over in seven Canadian provinces using linked healthcare databases.
Data Sources: Utilized the National Prescription Drug Utilization Information System (NPDUIS) for prescription claims and the Discharge Abstract Database (DAD) for hospital encounters.
Cohort Definition: Included individuals aged 66 and over with a newly dispensed AChEI between April 1, 2011, and January 31, 2019, excluding those with prior malignant arrhythmia hospitalizations.
Exposure and Follow-Up: Primary exposure was initiation of donepezil, with follow-up from the first prescription to the last, including a grace period for prescription gaps.
Outcome Definition: Primary outcome was hospitalization for a malignant arrhythmia, specifically ventricular tachycardia.
Key Findings:
Donepezil is associated with a higher risk of hospitalization for malignant arrhythmias compared to other AChEIs.
The study utilized a comprehensive dataset covering multiple provinces and a significant time frame.
Interpretation:
The findings suggest a potential increased risk of serious cardiac events associated with donepezil use in older adults.
Limitations:
The study is retrospective and may be subject to confounding factors.
Data was limited to publicly funded prescriptions and hospitalizations.
Conclusion:
The study highlights the need for careful monitoring of cardiac health in patients prescribed donepezil.
Moderate coffee consumption generally appeared safe for most adults, but randomized evidence suggested divergent effects on atrial fibrillation and premature ventricular contractions.
